4552 Stock Overview Engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
JCR Pharmaceuticals Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for JCR Pharmaceuticals Historical stock prices Current Share Price JP¥607.00 52 Week High JP¥1,228.00 52 Week Low JP¥466.00 Beta 0.017 1 Month Change -4.86% 3 Month Change -8.58% 1 Year Change -45.90% 3 Year Change -72.84% 5 Year Change -72.22% Change since IPO 172.81%
Recent News & Updates
JCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting Growth Hormone Therapy Dec 19
JCR Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025 Dec 18
JCR Pharmaceuticals (TSE:4552) Has Announced A Dividend Of ¥10.00 Dec 08
First half dividend of JP¥10.00 announced Dec 07
Medipal Holdings Corporation and Jcr Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for Mps IIIB in Japan Dec 03
Now 21% undervalued Nov 27 See more updates
JCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting Growth Hormone Therapy Dec 19
JCR Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025 Dec 18
JCR Pharmaceuticals (TSE:4552) Has Announced A Dividend Of ¥10.00 Dec 08
First half dividend of JP¥10.00 announced Dec 07
Medipal Holdings Corporation and Jcr Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for Mps IIIB in Japan Dec 03
Now 21% undervalued Nov 27
New minor risk - Share price stability Nov 09
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 01
JCR Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA Oct 31
JCR Pharmaceuticals Co., Ltd. Announces Interim Dividend Oct 30
JCR Pharmaceuticals Co., Ltd. Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress Oct 23
Upcoming dividend of JP¥10.00 per share Sep 20
JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00 Sep 06
What JCR Pharmaceuticals Co., Ltd.'s (TSE:4552) 32% Share Price Gain Is Not Telling You Sep 04
JCR Pharmaceuticals Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024 Aug 28
JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00 Aug 23
JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00 Aug 09
Investor sentiment deteriorates as stock falls 17% Aug 06
Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts Aug 03
First quarter 2025 earnings: EPS and revenues miss analyst expectations Aug 01
JCR Pharmaceuticals Co., Ltd Announces Discontinuation of TEMCELL HS Inj. Expanded Indication Development for Neonatal Hypoxic Ischemic Encephalopathy Jul 30
JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00 Jul 26
JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00 Jul 12
Final dividend of JP¥10.00 announced Jul 11
MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB Jul 01
Consensus EPS estimates fall by 17% Jun 08
JCR Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024 Jun 06
Price target decreased by 10% to JP¥1,314 May 23
JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely May 22
Investor sentiment deteriorates as stock falls 22% May 17
Full year 2024 earnings: EPS and revenues miss analyst expectations May 12
JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024 May 12
JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024 May 11
Upcoming dividend of JP¥10.00 per share Mar 21
JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion Mar 19
JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00 Mar 18 JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index (USD) Mar 18
JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024 Mar 02
JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00 Feb 29
JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes Feb 29
Now 22% overvalued Feb 16
JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier Feb 14
JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024 Feb 09
Price target decreased by 10% to JP¥1,657 Jan 30
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Jan 27
JCR Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Jan 26, 2024 Nov 29
New major risk - Share price stability Nov 02
JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA Oct 27
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Oct 27
JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024 Oct 26
New major risk - Revenue and earnings growth Oct 26
New major risk - Revenue and earnings growth Oct 05
JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I) Oct 01
Upcoming dividend of JP¥10.00 per share at 1.5% yield Sep 21
Investor sentiment improves as stock rises 18% Sep 15 PHC IVD and JCR Announce GROWJECTOR® Duo
JCR Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Oct 25, 2023 Aug 30 JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024
Consensus EPS estimates increase by 13% Aug 02
First quarter 2024 earnings released: EPS: JP¥12.90 (vs JP¥11.05 in 1Q 2023) Jul 27
Price target decreased by 7.4% to JP¥1,859 Jul 27
JCR Receives Approval to Start Global Phase I/II Clinical Trial for JR-441 for the Treatment of Mucopolysaccharidosis Type III A (MPS IIIA) Jul 12
Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes Jun 29
JCR Pharmaceuticals Co., Ltd. Receives an Approval for Expanded Indication of Growject®? in Short Stature Due to SHOX-Deficiency Jun 27
Full year 2023 earnings: EPS and revenues miss analyst expectations Jun 24
Consensus EPS estimates increase by 20% Jun 05 JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024
JCR Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Jul 26, 2023 May 28
Consensus EPS estimates fall by 24% May 21
Full year 2023 earnings: EPS and revenues miss analyst expectations May 13
JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023 May 12
Investor sentiment deteriorates as stock falls 18% May 12
Now 21% undervalued after recent price drop Mar 31
Consensus revenue estimates fall by 17% Mar 31
Upcoming dividend of JP¥10.00 per share at 1.3% yield Mar 23 JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
JCR Pharmaceuticals Co., Ltd. to Present Phase I/II Clinical Data on JR-171 Feb 15
Third quarter 2023 earnings released: EPS: JP¥20.89 (vs JP¥29.79 in 3Q 2022) Feb 01
U.S. Fda Grants Rare Pediatric Disease Designation for JCR Pharmaceuticals Co., Ltd. Jr-141 for Mpsii Jan 19
JCR Pharmaceuticals Co., Ltd. Appoints Yoh Ito as Senior Corporate Officer Dec 02
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 20 JCR Pharmaceuticals Announces Interim Dividend Payable on December 9, 2022; Provided Dividend Guidance for Fiscal 2023
Now 20% undervalued after recent price drop Nov 04
JCR to Initiate Development of New Drug Candidate for Fucosidosis Nov 01
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Oct 27
JCR Pharmaceuticals Co., Ltd. Announces Interim Dividend on Retained Earnings, Payable on December 9, 2022 Oct 27
Price target decreased to JP¥2,861 Oct 27
Now 21% undervalued after recent price drop Oct 21
Upcoming dividend of JP¥10.00 per share Sep 22
Jcr Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 Aug 24
JCR Pharmaceuticals Co., Ltd. Announces Update on Application for Manufacturing and Marketing Approval of JR-141 for Treatment of MPS II (Hunter Syndrome) in Brazil Aug 04
First quarter 2023 earnings released: EPS: JP¥11.05 (vs JP¥12.39 in 1Q 2022) Jul 30
JCR Pharmaceuticals Co., Ltd Files for Expanded Use GROWJECT for Short Stature Due to SHOX-Deficiency Jul 29 Shareholder Returns 4552 JP Pharmaceuticals JP Market 7D -7.0% -2.1% -1.9% 1Y -45.9% 11.1% 14.6%
See full shareholder returns
Return vs Market: 4552 underperformed the JP Market which returned 14.6% over the past year.
Price Volatility Is 4552's price volatile compared to industry and market? 4552 volatility 4552 Average Weekly Movement 5.8% Pharmaceuticals Industry Average Movement 3.8% Market Average Movement 3.6% 10% most volatile stocks in JP Market 7.3% 10% least volatile stocks in JP Market 1.9%
Stable Share Price: 4552's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4552's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease.
Show more JCR Pharmaceuticals Co., Ltd. Fundamentals Summary How do JCR Pharmaceuticals's earnings and revenue compare to its market cap? 4552 fundamental statistics Market cap JP¥73.95b Earnings (TTM ) -JP¥437.00m Revenue (TTM ) JP¥35.26b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4552 income statement (TTM ) Revenue JP¥35.26b Cost of Revenue JP¥10.07b Gross Profit JP¥25.19b Other Expenses JP¥25.62b Earnings -JP¥437.00m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
Earnings per share (EPS) -3.59 Gross Margin 71.44% Net Profit Margin -1.24% Debt/Equity Ratio 49.8%
How did 4552 perform over the long term?
See historical performance and comparison Dividends
3.3% Current Dividend Yield When do you need to buy 4552 by to receive an upcoming dividend? JCR Pharmaceuticals dividend dates Ex Dividend Date Mar 28 2025 Dividend Pay Date Jun 27 2025 Days until Ex dividend 97 days Days until Dividend pay date 188 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 23:20 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources JCR Pharmaceuticals Co., Ltd. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tatsuyuki Arai BofA Global Research Hidemaru Yamaguchi Citigroup Inc Kazuaki Hashiguchi Daiwa Securities Co. Ltd.
Show 10 more analysts 
